Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Despite conclusive evidence that it’s one of the most dangerous and addictive substances in the world, sugar is still widely used for a variety of purposes. In an effort to curb the effects of this sweet food, substitutes like aspartame have been introduced. Naturally, there were concerns about its supposed effects on health, but a recent study found that there were no causes for concern.
Recently published in The Journal of Nutrition, researchers basically looked into the effects of aspartame on several factors of health. These included glucose tolerance, weight, and appetite. The results indicated that the sugar substitute basically had no negative impact on any of those factors.
“With the exception of the baseline OGTT glucose concentration at 60 min (and resulting area under the curve value), there were no group differences for glucose, insulin, resting leptin, glucagon-like peptide 1, or gastric inhibitory peptide at baseline or week 12,” the results of the study reads. “There also were no effects of aspartame ingestion on appetite, body weight, or body composition.”
The study lasted for 12 weeks from start to finish, and throughout that period, the subjects were divided into three groups. One group took no aspartame while another took 350 mg per day. The third group took a much higher dosage of 1,050 mg of the sugar substitute.
Blood samples were taken from the subjects before the start of the trial and at the end of the 12-week course. Apparently, the participants did not show any significant differences in the factors that the researchers were looking at. In conclusion, the researchers note that their findings do not support the notion that aspartame comes with negative consequences such as obesity and an increase in rates of hunger.
On the other hand, Medical News Bulletin did note that the study received support from Ajinomoto Co., Inc., which produces products such as artificial sweeteners. However, the authors of the study insist that the findings of their aspartame research were not affected by the source of the funds.
